GSK enlists Chai Discovery for AI-generated biologics
Chai Discovery has signed a deal with GSK to use artificial intelligence in creating biologic medicines. The agreement builds on the startup’s earlier partnership with Eli Lilly, which CEO Joshua Meier framed at the start of 2026 as the beginning of a deployment-focused year. The article indicates Chai is expanding its AI-driven drug discovery work with large pharmaceutical partners.
Chai Discovery has reached an agreement with GSK to apply artificial intelligence toward creating biologic treatments. The arrangement follows Chai’s earlier collaboration with Eli Lilly, suggesting the startup is extending its work with major drugmakers.
CEO Joshua Meier described the start of 2026 as the beginning of a year focused on putting the technology into use. The company is widening its artificial-intelligence drug discovery efforts alongside large pharmaceutical companies, according to the available report.
If AI-assisted biologic development advances, patients could eventually see new treatment options, while researchers and drugmakers may change how they identify and test candidates. Health systems and payers might weigh evidence, cost, and access as such therapies move forward. The impact remains uncertain and depends on whether these collaborations produce safe, effective medicines.